Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry

SIMPLE SUMMARY: There is an urgent need to develop new treatments for patients with relapsed/refractory multiple myeloma (RRMM) to address unmet medical needs. Chimeric antigen receptor T-cell (CAR-T) therapy is a novel approach with the potential for long-term disease control. Ciltacabtagene autole...

Descripción completa

Detalles Bibliográficos
Autores principales: Merz, Maximilian, Goldschmidt, Hartmut, Hari, Parameswaran, Agha, Mounzer, Diels, Joris, Ghilotti, Francesca, Perualila, Nolen J., Cabrieto, Jedelyn, Haefliger, Benjamin, Sliwka, Henrik, Schecter, Jordan M., Jackson, Carolyn C., Olyslager, Yunsi, Akram, Muhammad, Nesheiwat, Tonia, Kellermann, Lenka, Jagannath, Sundar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656798/
https://www.ncbi.nlm.nih.gov/pubmed/34885106
http://dx.doi.org/10.3390/cancers13235996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656798/
https://www.ncbi.nlm.nih.gov/pubmed/34885106
http://dx.doi.org/10.3390/cancers13235996

Ejemplares similares